Skip to content
stoqly

Amneal Pharmaceuticals

AMRX Nasdaq Pharmaceuticals Financials FY2016–FY2025

Amneal Pharmaceuticals' revenue rose 8.1% to $3.0 billion in fiscal 2025. Its operating margin was 13.1%, up from 8.9% a year earlier. Free cash flow was $270 million, up 11.0%. The diluted share count rose 5.1%.

Last close · Oct 23, 2026

$20.38

0.5%
Value it Compare
Revenue Total sales reported in the income statement.
$3.0B
8.0% vs prior year
Operating margin Operating income as a share of revenue.
13.1%
4.1 pts
Net income Profit after all expenses, interest and tax.
$72.1M
Free cash flow Cash from operations minus capital spending.
$270M
11.0%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
16.1%
7.6 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$6.7B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
41.6x
On $0.49 EPS (TTM)

What Amneal Pharmaceuticals does

No business description yet.

Legal name
AMNEAL PHARMACEUTICALS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001723128-26-000011
0001723128

Revenue and margins

Amneal Pharmaceuticals had $3.0B of revenue in fiscal 2025, up 8.1% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $270M in fiscal 2025, 8.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Amneal Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 5.1%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Amneal Pharmaceuticals yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.3B and divides by 324.8M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 41.6x · peers 14.6x · sector 27.9x.

Balance sheet

Cash, debt and the ratios that show how comfortably Amneal Pharmaceuticals can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $248M$26.0M$91.5M$111M$282M
Debt incl. finance leases $2.8B$2.7B$2.5B$2.4B$2.6B
Net debt / EBITDA 6.5x18.3x5.5x4.8x3.8x
Debt / equity 7.7x9.0x———
Interest coverage 1.3x−0.7x1.1x1.0x2.0x
Current ratio 2.2x1.9x1.6x1.4x2.2x
Quick ratio 1.5x1.2x0.9x0.9x1.5x
Total assets $3.9B$3.8B$3.5B$3.5B$3.7B
Total liabilities $3.6B$3.6B$3.5B$3.6B$3.7B
Shareholders' equity $360M$298M$19.8M−$109M−$70.8M
Net debt (− = net cash) $2.5B$2.7B$2.4B$2.3B$2.3B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$9.8M

5 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Aug 13, 2026 John KielyDirector Sold 50,000 $17.64 $0.9M Form 4
Aug 12, 2026 Jason B. DalyEVP, Chief Legal Officer Sold 210,000 $17.40 $3.7M Form 4
Aug 12, 2026 Nikita ShahExecutive Vice President Sold 146,403 $17.51 $2.6M Form 4
Aug 11, 2026 Jason B. DalyEVP, Chief Legal Officer Sold 6,613 $17.70 $0.1M Form 4
May 11, 2026 Deborah M. AutorDirector Sold 34,819 $12.94 $0.5M Form 4
Nov 17, 2025 Ted C NarkDirector Sold 50,000 $11.72 $0.6M Form 4
Nov 12, 2025 Nikita ShahExecutive Vice President Sold 131,856 $11.92 $1.6M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✕ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✕ ✕
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✕ ✕ ✕
Gross margin rose ✕ ✓ ✓
Revenue rose relative to assets ✓ ✓ ✓
F-score 5 / 94 / 97 / 9
Accruals ratio −11.8%−11.8%−7.5%
Altman Z'' 0.950.742.06

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Amneal Pharmaceuticals AMRX $6.7B 8.1% 13.1% 8.9% 16.1% 41.6x 7
Jazz Pharmaceuticals JAZZ $14.9B 4.9% −10.1% 30.4% −4.2% 14.6x 4 Compare →
Elanco ELAN $11.4B 6.2% — 6.0% −0.1% — 6 Compare →
Alkermes ALKS $7.6B −5.3% 17.2% 32.6% — 114.8x — Compare →
Indivior INDV $4.3B 4.3% 21.2% −7.5% — 12.4x 4 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $1.0B $1.0B $1.7B $1.6B $2.0B $2.1B $2.2B $2.4B $2.8B $3.0B
Gross profit $598M $526M $716M $353M $628M $769M $785M $821M $1.0B $1.1B
Research and development $179M $171M $194M $188M $180M $202M $196M $164M $191M $186M
Operating income $285M $245M −$19.7M −$249M $91.2M $153M −$94.9M $204M $249M $394M
Interest expense $50.6M $65.1M $132M $159M $130M $122M $143M $193M $264M $198M
Pretax income $215M $171M −$203M −$220M −$35.8M $31.4M −$248M −$40.3M −$55.0M $139M
Income tax $5.4M $2.0M −$1.4M $383M −$104M $11.2M $6.7M $8.5M $18.9M $11.3M
Net income $0.0M $0.0M −$19.7M −$604M $67.8M $13.2M −$271M −$84.0M −$117M $72.1M
Diluted EPS — — −$0.16 −$2.74 $0.61 $0.07 −$0.86 −$0.48 −$0.38 $0.22
Diluted shares — — 0.13B 0.13B 0.15B 0.15B 0.15B 0.18B 0.31B 0.32B
Cash flow
Cash from operations $115M $234M $250M $1.7M $379M $242M $65.1M $346M $295M $340M
Capital expenditure $123M $94.8M $83.1M $47.2M $56.4M $47.7M $46.4M $43.2M $51.9M $70.1M
Free cash flow −$7.7M $139M $167M −$45.5M $323M $194M $18.7M $302M $243M $270M
Depreciation and amortization $33.0M $115M $208M $207M $235M $233M $240M $229M $236M $224M
Stock-based compensation $0.0M $0.0M $168M $21.7M $20.8M $28.4M $31.8M $26.8M $27.8M $32.0M
Acquisitions $0.0M $0.0M $325M $0.0M $251M $147M $84.7M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends paid $201M $375M $183M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $201M $375M $183M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Balance sheet
Cash and short-term investments $27.4M $74.2M $213M $151M $341M $248M $26.0M $91.5M $111M $282M
Total debt — $1.4B $2.7B $2.6B $2.8B $2.7B $2.6B $2.4B $2.4B $2.6B
Finance lease liabilities $0.0M $0.0M $0.0M $62.5M $65.5M $63.4M $64.3M $61.0M $60.1M $58.4M
Current assets — $772M $1.3B $1.2B $1.6B $1.5B $1.4B $1.4B $1.6B $1.9B
Current liabilities — $297M $554M $550M $677M $677M $753M $847M $1.1B $882M
Inventory $0.0M $284M $457M $381M $491M $489M $531M $581M $613M $606M
Property and equipment, net — $487M $544M $478M $478M $514M $470M $448M $425M $443M
Total assets — $1.3B $4.4B $3.7B $4.0B $3.9B $3.8B $3.5B $3.5B $3.7B
Total liabilities — $0.0M $3.5B $3.3B $3.7B $3.6B $3.6B $3.5B $3.6B $3.7B
Shareholders' equity — $0.0M $505M $232M $303M $360M $298M $19.8M −$109M −$70.8M
Margins
Gross margin 58.7% 50.9% 43.1% 21.7% 31.5% 36.7% 35.5% 34.3% 36.5% 36.9%
Operating margin 28.0% 23.7% −1.2% −15.3% 4.6% 7.3% −4.3% 8.5% 8.9% 13.1%
EBITDA margin 31.2% 34.8% 11.4% −2.6% 16.4% 18.4% 6.6% 18.1% 17.4% 20.5%
Net margin 0.0% 0.0% −1.2% −37.1% 3.4% 0.6% −12.2% −3.5% −4.2% 2.4%
FCF margin −0.8% 13.5% 10.1% −2.8% 16.2% 9.3% 0.8% 12.6% 8.7% 8.9%
Returns
Return on capital — — −0.7% −6.3% 2.5% 3.4% −2.6% 6.2% 8.5% 16.1%
Return on capital employed — — −0.8% −7.2% 2.8% 4.6% −3.0% 7.2% 10.0% 15.3%
Return on equity — — −7.8% −163.9% 25.3% 4.0% −82.2% — — —
Return on assets — — −0.7% −15.1% 1.8% 0.3% −7.0% −2.3% −3.4% 2.0%
Growth
Revenue growth — 1.5% 60.9% −2.2% 22.5% 5.1% 5.7% 8.2% 16.7% 8.1%
Net income growth — — — — — −80.6% −2,155.6% — — —
EPS growth — — — — — −88.5% −1,328.6% — — —
FCF growth — — 19.9% −127.2% — −39.8% −90.4% 1,517.5% −19.6% 11.0%
Share count change — — — 3.8% 12.7% 2.0% −0.6% 16.7% 75.4% 5.1%
Financial health
Net debt / EBITDA — 3.8x 12.9x — 7.7x 6.5x 18.3x 5.5x 4.8x 3.8x
Debt / equity — — 5.3x 11.6x 9.4x 7.7x 9.0x — — —
Interest coverage 5.6x 3.8x −0.2x −1.6x 0.7x 1.3x −0.7x 1.1x 1.0x 2.0x
Current ratio — 2.6x 2.3x 2.2x 2.3x 2.2x 1.9x 1.6x 1.4x 2.2x
Quick ratio — 1.6x 1.5x 1.5x 1.6x 1.5x 1.2x 0.9x 0.9x 1.5x
Capital allocation
Capex / revenue 12.1% 9.2% 5.0% 2.9% 2.8% 2.3% 2.1% 1.8% 1.9% 2.3%
Stock comp / revenue 0.0% 0.0% 10.1% 1.3% 1.0% 1.4% 1.4% 1.1% 1.0% 1.1%
Payouts / FCF — 269.2% 109.5% — 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Quality scores
Piotroski F-score — — — 3.0 7.0 5.0 5.0 5.0 4.0 7.0
Altman Z'' — — 1.3 0.5 1.5 1.5 0.7 1.0 0.7 2.1
Accruals ratio — — −9.5% −15.1% −8.1% −5.8% −8.7% −11.8% −11.8% −7.5%

Source: SEC EDGAR XBRL filings (CIK 0001723128). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open